SECOND AMENDMENT AND EXTENSION OF STANDSTILL AND FORBEARANCE AGREEMENTStandstill and Forbearance Agreement • February 2nd, 2021 • GT Biopharma, Inc. • Pharmaceutical preparations
This Second Amendment and Extension of Standstill and Forbearance Agreement (this “Agreement”) is entered into as of January 31, 2021, by and between GT Biopharma, Inc., a Delaware corporation (the “Company”), and [●] (the “Lender”), with respect to that certain Standstill and Forbearance Agreement, dated as of June 23, 2020, between the Company and the Lender (as amended, supplemented, or otherwise modified from time to time, the “Forbearance Agreement”). Any capitalized term used in this Agreement and not otherwise defined shall have the meaning ascribed to it in the Forbearance Agreement.
AMENDMENT TO CONVERTIBLE NOTEConvertible Note Amendment • February 2nd, 2021 • GT Biopharma, Inc. • Pharmaceutical preparations
This Amendment to Convertible Note (this “Amendment”) is entered into as of January [●], 2021 (the “Effective Date”), by and between GT Biopharma, Inc., a Delaware corporation (the “Borrower”) and [●] (the “Holder” and together with the Borrower, the “Parties”) with respect to that certain Convertible Note Due January 31, 2021, dated November 9, 2020, in the original principal amount of $303,726.40 (the “Note”). Any capitalized term used in this Amendment and not otherwise defined shall have the meaning ascribed to it in the Note.
